A systematic review of the use of rituximab for desensitization in renal transplantation

Transplantation

Volumn 98, Issue 8, 2014, Pages 794-805

  Macklin, Philip S ^a   Morris, Peter J ^a,b   Knight, Simon R ^a,b  

^a Centre for Evidence in Transplantation (CET) Clinical Effectiveness Unit RCSE   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Desensitization; Renal; Rituximab; Transplantation

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BASILIXIMAB; BORTEZOMIB; CORTICOSTEROID; CYCLOSPORIN A; DACLIZUMAB; IMMUNOGLOBULIN; LYMPHOCYTE ANTIBODY; MIZORIBINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISOLONE; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY; ALLOANTIBODY; BLOOD GROUP ABO SYSTEM; MONOCLONAL ANTIBODY;

ACUTE GRAFT REJECTION; ANTIBODY MEDIATED REJECTION; ANTIBODY TITER; BLOOD GROUP ABO INCOMPATIBILITY; BLOODSTREAM INFECTION; CHRONIC GRAFT REJECTION; COLITIS; COMBINATION CHEMOTHERAPY; CYTOMEGALOVIRUS INFECTION; DESENSITIZATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG USE; ESOPHAGITIS; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; INFECTIOUS COMPLICATION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LOW DRUG DOSE; MONOTHERAPY; PERITONITIS; PLASMAPHERESIS; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SKIN INFECTION; SOFT TISSUE INFECTION; SPLENECTOMY; SYSTEMATIC REVIEW; BLOOD; BLOOD GROUP ABO SYSTEM; BLOOD GROUP INCOMPATIBILITY; DONOR; HISTOCOMPATIBILITY TEST; IMMUNOLOGY;

ABO BLOOD-GROUP SYSTEM; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; BLOOD GROUP INCOMPATIBILITY; DESENSITIZATION, IMMUNOLOGIC; HISTOCOMPATIBILITY TESTING; HUMANS; ISOANTIBODIES; KIDNEY TRANSPLANTATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TISSUE DONORS;

EID: 84922013250     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000362     Document Type: Review

References (91)

1. Evans RW, Manninen DL, Garrison LP Jr, et al. The quality of life of patients with end-stage renal disease. N Engl J Med 1985; 312: 553.
2. Port FK, Wolfe RA, Mauger EA, et al. Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients. JAMA 1993; 270: 1339.
3. Russell JD, Beecroft ML, Ludwin D, et al. The quality of life in renal transplantationVa prospective study. Transplantation 1992; 54: 656.
4. Cai J, Terasaki PI. The current trend of induction and maintenance treatment in patient of different PRA levels: a report on OPTN/UNOS Kidney Transplant Registry data. Clin Transpl 2010; 45.
5. Lefaucheur C, Suberbielle-Boissel C, Hill GS, et al. Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation. Am J Transplant 2008; 8: 324.
6. Lefaucheur C, Nochy D, Hill GS, et al. Determinants of poor graft outcome in patients with antibody-mediated acute rejection. Am J Transplant 2007; 832.
7. Reisaeter AV, Leivestad T, Albrechtsen D, Holdaas H, et al. Pretrans-plant plasma exchange or immunoadsorption facilitates renal transplantation in immunized patients. Transplantation 1995; 60: 242.
8. Worthington JE, Martin S, Dyer PA, et al. An association between posttransplant antibody production and renal transplant rejection. Transplant Proc 2001; 33: 475.
9. Gloor JM, Lager DJ, Moore SB, et al. ABO-incompatible kidney transplantation using both A2 and non-A2 living donors. Transplantation 2003; 75: 971.
10. Tedder TF, Forsgren A, Boyd AW, Nadler LM, Schlossman SF. Antibodies reactive with the B1 molecule inhibit cell cycle progression but not activation of human B lymphocytes. Eur J Immunol 1986; 16: 881.
11. Sureshkumar KK, Hussain SM, Carpenter BJ, et al. Antibody-mediated rejection following renal transplantation. Expert Opin Pharmacother 2007; 8: 913.
12. Jordan SC, Vo AA, Tyan D, et al. Current approaches to treatment of antibody-mediated rejection. Pediatr Transplant 2005; 9: 408.
13. Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 2188.
14. De Vita S, Zaja F, Sacco S, et al. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. Arthritis Rheum 2002; 46: 2029.
15. Kneitz C, Wilhelm M, Tony HP. Effective B cell depletion with rituximab in the treatment of autoimmune diseases. Immunobiology 2002; 206: 519.
16. Vo AA, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008; 359: 242.
17. Kohei N, Hirai T, Omoto K, et al. Chronic antibody-mediated rejection is reduced by targeting B-cell immunity during an introductory period. Am J Transplant 2012; 12: 469.
18. Fuchinoue S, Ishii Y, Sawada T, et al. The 5-year outcome of ABO-incompatible kidney transplantation with rituximab induction. Transplantation 2011; 91: 853.
19. Tanabe K, Ishida H, Shimizu T, et al. Evaluation of two different preconditioning regimens for ABO-incompatible living kidney donor transplantation. Acomparison of splenectomy vs. rituximab-treated non-splenectomy preconditioning regimens. Contrib Nephrol 2009; 162: 61.
20. Toki D, Ishida H, Horita S, et al. Blood group O recipients associated with early graft deterioration in living ABO-incompatible kidney transplantation. Transplantation 2009; 88: 1186.
21. Tanabe K. Japanese experience of ABO-incompatible living kidney transplantation. Transplantation 2007; 84: S4.
22. Ashimine S, Watarai Y, Yamamoto T, et al. Neither pre-transplant rituximab nor splenectomy affects de novo HLA antibody production after renal transplantation. Kidney Int 2014; 85: 425.
23. Montgomery RA, Locke JE, King KE, et al. ABO incompatible renal transplantation: a paradigm ready for broad implementation. Transplantation 2009; 87: 1246.
24. Gloor JM, Lager DJ, Fidler ME, et al. A Comparison of splenectomy versus intensive posttransplant antidonor blood group antibody monitoring without splenectomy in ABO-incompatible kidney transplantation. Transplantation 2005; 80: 1572.
25. Waigankar SS, Kamat MH, Joshi S, et al. Living donor transplant options in end-stage renal disease patients with ABO incompatibility. Indian J Urol 2013; 29: 114.
26. Stegall MD, Gloor J, Winters JL, et al. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 2006; 6: 346.
27. Ishida H, Furusawa M, Shimizu T, et al. Influence of preoperative anti-HLA antibodies on short-and long-term graft survival in recipients with or without rituximab treatment. Transpl Int 2014; 27: 371.
28. Hirai T, Kohei N, Omoto K, et al. Significance of low-level DSA detected by solid-phase assay in association with acute and chronic antibody-mediated rejection. Transpl Int 2012; 25: 925.
29. Loupy A, Suberbielle-Boissel C, Zuber J, et al. Combined posttrans-plant prophylactic IVIg/Anti-CD 20/plasmapheresis in kidney recipients with preformed donor-specific antibodies: a pilot study. Transplantation 2010; 89: 1403.
30. Song YH, Huh KH, Kim YS, et al. Impact of pretransplant rituximab induction on highly sensitized kidney recipients: comparison with non-rituximab group. J Korean Surg Soc 2012; 82: 335.
31. Ejaz NS, Shields AR, Alloway RR, et al. Randomized controlled pilot study of B cell-targeted induction therapy in HLA sensitized kidney transplant recipients. Am J Transplant 2013; 13: 3142.
32. Nishida H, Ishida H, Tanaka T, et al. Cytomegalovirus infection following renal transplantation in patients administered low-dose rituximab induction therapy. Transpl Int 2009; 22: 961.
33. Grim SA, Pham T, Thielke J, et al. Infectious complications associated with the use of rituximab for ABO-incompatible and positive cross-match renal transplant recipients. Clin Transplant 2007; 21: 628.
34. Hyodo Y, Shishido S, Kawamura T, et al. MMF and Rituximab Had Great Beneficial Effects on Improving ABO Incompatible Kidney Transplantation [abstract]. Transplant International 2011; 24(suppl 2): 131.
35. Aikawa A, Takahashi K, Saito K. ABO Incompatible Pediatric Kidney Transplantation in Japan [abstract]. Pediatric Transplantation 2011; 15(suppl 1): 43.
36. Ishii Y, Iwadoh K, Murakami T, et al. Impact of Rituximab Induction Therapy on CMV Infectious Disease in ABO Incompatible Kidney Transplantation [abstract]. Transplant International 2011; 24(suppl 2): 279.
37. Ishii Y, Iwadoh K, Murakami T, et al. Examination of CMV Infectious Disease in ABO Incompatible Kidney Transplant Using Rituximab [abstract]. American Journal of Transplantation 2011; 24(suppl 2): 480.
38. Tomita Y, Ishii Y, Murakami T, et al. The 5-Year Outcome of ABO Incompatible Kidney Transplantation With Rituximab Induction [abstract]. American Journal of Transplantation 2011; 24(suppl 2): 250.
39. Tanabe K, Ishida H, Kouhei N, et al. Significant Reduction in Chronic Antibody-Mediated Rejection After B-cell Depleting Treatment in ABO-Incompatible Living Kidney Transplantation [abstract]. American Journal of Transplantation 2011; 24(suppl 2): 111.
40. Miyauchi Y, Hirai T, Tokita D, et al. Marked Improvement of the Outcome of ABO-Incompatible Living Kidney Transplantation Under Current Immunosuppressive Regimen [abstract]. American Journal of Transplantation 2010; 10(suppl 4): 219.
41. Kohei N, Hirai T, Sai K, et al. B Cell Depletion Therapy for ABO Incompatible Kidney Transplantation Prevent Chronic Antibody Mediated Rejection [abstract]. American Journal of Transplantation 2010; 10(suppl 4): 416.
42. Harada H, Sasaki H, Hotta K, et al. A Single Low Dose Rituximab Ensures Excellent Outcome of ABO Incompatible Kidney Transplantation [abstract]. Xenotransplantation 2013; 13(suppl 5): 320.
43. Charif R, De Kort H, Roufosse C, et al. Rituximab or Alemtuzumab Induction for ABO Incompatible Renal Transplantation?. American Journal of Transplantation 2013; 13(suppl 5): 283.
44. Nakagawa Y, Saito K, Takahashi K. The Clinical Study of Immuno-suppression Protocol in ABO-Incompatible Kidney Transplantation [abstract]. Transplant International 2011; 24(suppl 2): 36.
45. Umanath K, Shaffer D, Feurer I, et al. Rituximab Significantly Improves Rejection Free Graft Survival When Added to High Dose IVIG in Patients With Positive Crossmatch Undergoing Kidney Transplantation [abstract]. American Journal of Transplantation 2012; 12(suppl 3): 228.
46. Ishida H, Shimizu T, Furusawa M, et al. Influence of Preoperative Anti-HLA Antibodies on Short-Term and Long-Term Graft Survival in Recipients With Or Without Rituximab Treatment [abstract]. American Journal of Transplantation 2013; 13(suppl 5): 76.
47. Hirai T, Sawada Y, Nozaki T, et al. The Significance of Low Level DSA Detected by Solid Phase Assay in Association With Acute and Chronic Antibody Mediated Rejection [abstract]. Transplantation 2012; 94(suppl 10): 1067.
48. Hirai T, Sawada Y, Tanabe T, et al. The Significance of Low Level DSA Detected by Solid Phase Assay in Association With Acute and Chronic Antibody Mediated Rejection [abstract]. American Journal of Transplantation 2012; 12(suppl 3): 150.
49. Hirai T, Tanabe T, Kohei N, et al. Successful Prevention of Chronic AMR in DSA-Positive Kidney Transplantation by Rituximab-Based Preconditioning [abstract]. Transplant International 2011; 24(suppl 2): 38.
50. Tanabe K, Ishida H, Omoto K, et al. Excellent Long-Term Outcomes of Donor-Specific Anti-HLA Antibody (DSA) Positive Renal Transplant Recipients and Significant Elimination of Posttransplant DSA by Combination Treatment of Basiliximab and Rituxaimab Induction [abstract]. American Journal of Transplantation 2010; 10(suppl 4): 221.
51. Amrouche L, Loupy A, Suberbielle C, et al. Post-Transplant Desensi-tization With IVIg/Anti-CD20/Plasmapheresis in DSA+ Kidney Recipients Decreases CAMR Incidence [abstract]. American Journal of Transplantation 2012; 12(suppl 3): 151.
52. Loupy A, Suberbielle C, Anglicheau D, et al. Prophylactic Anti-CD20 Combined With Plasmapheresis (PP) Reduces Chronic AMR in Kidney Transplant Recipients (KTR) With Preexisting DSAs [abstract]. American Journal of Transplantation 2009; 9(suppl 2): 273.
53. Vo A, Choi J, Lukovsky M, et al. Interim Analysis of a Double-Blinded Placebo Controlled Trial of IVIG v. IVIG+Rituximab for Desensiti-zation of Highly-HLA Sensitized (PRA 980%) (HS) Deceased Donor (DD) candidates [abstract]. American Journal of Transplantation 2013; 13(suppl 5): 76.
54. Vo A, Choi J, Kahwaji J, et al. Long Term Outcomes of Highly-HLA Sensitized (PRA980%) (HS) Patients Receiving Desensitization With IVIG or IVIG+Rituximab: A Retrospective, Single-Center Analysis [abstract]. American Journal of Transplantation 2013; 13(suppl 5): 284.
55. Vo AA, Peng A, Toyoda M, et al. Comparison of Desensitization Using High-Dose (HD) IVIG vs. HD-IVIG+Rituximab in Highly-Sensitized Patients With PRAs 9Eighty Percent (HS) [abstract]. American Journal of Transplantation 2010; 10(suppl 4): 221.
56. Joo DJ, Lee HS, Huh KH, et al. Impact of Pretransplant Rituximab on Kidney Graft in Highly-Sensitized Recipients; Compared With Non-Rituximab Group [abstract]. Transplantation 2012; 94(suppl 10): 1068.
57. Kim MS, Huh KH, Joo DJ, et al. Impact of Pretransplant Rituximab Induction on Kidney Graft in Highly Sensitized Recipients [abstract]. American Journal of Transplantation 2012; 12(suppl 3): 318.
58. Laftavi M, Patel S, Kohli R, et al. Combined Induction Therapy With Rabbit Antithymocyte Globulin (RATG) and Rituximab (RTX) in Highly Sensitized Kidney Recipients: Long-Term Outcomes [abstract]. American Journal of Transplantation 2013; 13(suppl 5): 427.
59. Laftavi MR, Seepana V, Alnimri M, et al. Highly Sensitized Kidney Recipients (PRA980%) Benefit From Rabbit Antithymocyte Globulin (rATG) and Rituximab Induction Therapy [abstract]. American Journal of Transplantation 2011; 11(suppl 2): 487.
60. Ejaz N, Shields A, Alloway R, et al. A Prospective, Randomized Pilot Study of B-Cell Targeted Induction Therapy in Sensitized Kidney Transplant Recipients: Final Report [abstract]. American Journal of Transplantation 2013; 13(suppl 5): 84.
61. Schmidt N, Shields AR, Alloway RR, et al. Randomized Controlled Trial of B-Cell Targeted Induction Therapy in HLA Sensitized Kidney Transplant Recipients: Preliminary Results [abstract]. American Journal of Transplantation 2012; 12(suppl 3): 56.
62. Starzl TE, Marchioro TL, Holmes JH, et al. Renal homografts in patients with major donor-recipient blood group incompatibilities. Surgery 1964; 55: 195.
63. Takahashi K, Saito K, Takahara S, et al. Excellent long-term outcome of ABO-incompatible living donor kidney transplantation in Japan. Am J Transplant 2004; 4: 1089.
64. Tydén G, Kumlien G, Fehrman I. Successful ABO-incompatible kidney transplantations without splenectomy using antigen-specific immunoadsorption and rituximab. Transplantation 2003; 76: 730.
65. Sonnenday CJ, Warren DS, Cooper M, et al. Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy. Am J Transplant 2004; 4: 1315.
66. Steinmetz OM, Lange-Husken F, Turner JE, et al. Rituximab removes intrarenal B cell clusters in patients with renal vascular allograft rejection. Transplantation 2007; 84: 842.
67. Zachary AA, Lucas DP, Montgomery RA, et al. Rituximab prevents an anamnestic response in patients with cryptic sensitization to HLA. Transplantation 2013; 95: 701.
68. Tydén G, Donauer J, Wadstrom J, et al. Implementation of a protocol for ABO-incompatible kidney transplantationVa three-center experience with 60 consecutive transplantations. Tr a n s p l a n t a t i o n 2007; 83: 1153.
69. Genberg H, Kumlien G, Wennberg L, et al. ABO-incompatible kidney transplantation using antigen-specific immunoadsorption and rituximab: a 3-year follow-up. Transplantation 2008; 85: 1745.
70. Cadili A, de Gara C. Complications of splenectomy. Am J Med 2008; 121: 371.
71. Vo AA, Petrozzino J, Yeung K, et al. Efficacy, outcomes, and cost-effectiveness of desensitization using IVIG and rituximab. Transplantation 2013; 95: 852.
72. Maloney DG, Grillo-Lopez AJ, Bodkin DJ, et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1997; 15: 3266.
73. Ng CM, Bruno R, Combs D, et al. Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial. J Clin Pharmacol 2005; 45: 792.
74. Genberg H, Hansson A, Wernerson A, et al. Pharmacodynamics of rituximab in kidney allotransplantation. Am J Transplant 2006; 6: 2418.
75. Genberg H, Hansson A, Wernerson A, et al. Pharmacodynamics of rituximab in kidney transplantation. Transplantation 2007 Dec 27; 84: S33.
76. Toki D, Ishida H, Horita S, et al. Impact of low-dose rituximab on splenic B cells in ABO-incompatible renal transplant recipients. Transpl Int 2009; 22: 447.
77. Takagi T, Ishida H, Shirakawa H, et al. Evaluation of low-dose rituximab induction therapy in living related kidney transplantation. Transplantation 2010; 89: 1466.
78. Maloney DG, Liles TM, Czerwinski DK, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lym-phoma. Blood 1994; 84: 2457.
79. Agarwal A, Vieira CA, Book BK, et al. Rituximab, anti-CD20, induces in vivo cytokine release but does not impair ex vivo T-cell responses. Am J Transplant 2004; 4: 1357.
80. Zarkhin V, Li L, Kambham N, et al. A randomized, prospective trial of rituximab for acute rejection in pediatric renal transplantation. Am J Transplant 2008; 8: 2607.
81. Kamar N, Milioto O, Puissant-Lubrano B, et al. Incidence and predictive factors for infectious disease after rituximab therapy in kidney-transplant patients. Am J Transplant 2010; 10: 89.
82. Scemla A, Loupy A, Candon S, et al. Incidence of infectious complications in highly sensitized renal transplant recipients treated by rituximab: a case-controlled study. Transplantation 2010; 90: 1180.
83. Kahwaji J, Sinha A, Toyoda M, et al. Infectious complications in kidney-transplant recipients desensitized with rituximab and intravenous immunoglobulin. Clin J Am Soc Nephrol 2011; 6: 2894.
84. van Vollenhoven RF, Emery P, Bingham CO 3rd, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis 2013; 72: 1496.
85. Chung BH, Yun JT, Ha SE, et al. Combined use of rituximab and plasmapheresis pre-transplant increases post-transplant infections in renal transplant recipients with basiliximab induction therapy. Transpl Infect Dis 2013; 15: 559.
86. Barbosa D, Kahwaji J, Puliyanda D, et al. Polyomavirus BK Viremia in Kidney Transplant Recipients After Desensitization With IVIG and Rituximab. Transplantation November 21, 2013. E-pub ahead of print.
87. Kamar N, Mengelle C, Rostaing L. Incidence of JC-virus replication after rituximab therapy in solid-organ transplant patients. Am J Transplant 2009; 9: 244.
88. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339: b2535.
89. Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 1998; 52: 377.
90. Deeks JJ, Dinnes J, D'Amico R, et al. Evaluating non-randomised intervention studies. Health Technol Assess 2003; 7: 1.
91. OCEBM Levels of Evidence Working Group. The Oxford Levels of Evidence 2. Oxford Centre for Evidence-Based. http://www.cebm.net/index.aspx?o=5653. Accessed 30th July 2014.